According to the company, the vaccines have demonstrated safety and efficacy in study with animal models.
Sinovac has developed the PPV and will retain full commercialization rights to the vaccine upon approval.
Sinovac chairman & CEO said Weidong Yin said PPV is the first bacterial vaccine for which the company has submitted the clinical trial application to the SFDA, representing their expansion of the R&D capabilities to include both bacterial and virus vaccines.
"The establishment of our bacterial vaccine development platform will accelerate the R&D for the pneumococcal conjugate vaccine and other types of bacterial vaccines in our pipeline, such as the HIB and meningitis vaccines," Yin said.